


# TREATMENT PROTOCOL USING DOXERCALCIFEROL (HECTOROL®) AND CAP AND THE CAP/CIP RATIO

Richard Amerling. Beth Israel Med. Ctr., New York, NY, USA.

Using bone histology, Tokumoto has demonstrated that the criteria: CAP <90 pgm/ml or a 1-84 PTH/7-84 PTH (CAP/CIP) ratio of <1.4, accurately identify adynamic bone disease patients with a 100% specificity and a 94% sensitivity. It is important to administer a small dose of vitamin D to ESRD patients to compensate for the loss of the kidney as a source of active vitamin D. We have incorporated these considerations into a treatment protocol with the use of doxercalciferol (Hectorol®).

## The CAP and CAP/CIP Ratio Treatment Guideline Using Hectorol (Doxercalciferol)



\* Provided that the serum calcium is <10.2 mg/dL and the Calcium x Phosphate product is <55. If serum calcium is >10.2 mg/dL or Calcium x Phosphate product is >55 - reduce dose by 50%. Doses are IV 3X/week.

**Monthly PTH measurements until PTH values and dosing changes have stabilized**

Amerling R. Treatment Protocol using Doxercalciferol (Hectorol®) and Intact PTH and the CAP/CIP Ratio. *Am J Kidney Dis* 2004(April); 43(4):9, pp. A17.